CJC-1295 DAC (2mg Vial) Dosage Protocol
Quickstart Highlights
CJC-1295 DAC (2mg) dosage protocol is designed to elevate and prolong growth hormone (GH) and IGF-1 levels via once-weekly subcutaneous injections.
- Extended half-life allows weekly administration
- Typical dosing ranges from 0.3 mg to 2 mg per week in standard protocols
- Advanced protocols may go beyond 2 mg weekly
- Reconstitute to a practical concentration for accurate dosing
- Store lyophilized vials frozen; refrigerate after reconstitution
Dosing & Reconstitution Guide
Educational guide for reconstitution and once-weekly dosing protocol
Standard / Gradual Approach (0.8 mL = 2.5 mg/mL)
| Week | Weekly Dose (mg) | Units (per injection) |
|---|---|---|
| Weeks 1–4 | 0.3 mg | 12 units |
| Weeks 5–8 | 0.6 mg | 24 units |
| Weeks 9–12 | 1 mg | 40 units |
| Weeks 13–16 (Optional) | 2 mg | 80 units |
Ideal for moderate weekly doses (up to ~2 mg). Reconstitute each 2 mg vial with 0.8 mL of bacteriostatic water to create a 2.5 mg/mL solution.
- Draw 0.8 mL of bacteriostatic water into a sterile syringe.
- Inject the water slowly along the vial wall to minimize foaming.
- Gently swirl—avoid vigorous shaking.
- Store the reconstituted solution at 2–8 °C (refrigerator), protected from light.
Note: For higher doses (e.g., 2 mg in Weeks 13–16), you will use the entire vial in a single injection (80 units). Multiple vials may be required to sustain the full protocol.
Advanced / Aggressive Approach (0.4 mL = 5 mg/mL)
| Week | Weekly Dose (mg) | Units (per injection) |
|---|---|---|
| Weeks 1–4 | 1 mg | 20 units |
| Weeks 5–8 | 2 mg | 40 units |
| Weeks 9–12 | 3 mg | 60 units |
| Weeks 13–16 (Optional) | 4 mg | 80 units |
Recommended if aiming for higher weekly doses (1–4 mg). Reconstitute each 2 mg vial with 0.4 mL of bacteriostatic water to create a 5 mg/mL solution.
Important: If your protocol calls for 3 mg or 4 mg in a single week, you will need multiple vials, as one vial only contains 2 mg total.
- Draw 0.4 mL of bacteriostatic water into a sterile syringe.
- Slowly inject the water along the vial wall to reduce foaming.
- Gently roll or swirl the vial—avoid vigorous shaking.
- Store the reconstituted solution at 2–8 °C (refrigerator), protected from light.
Protocol Overview
A concise summary of this once-weekly regimen.
- Goal: Sustain elevated GH and IGF-1 levels for research purposes
- Schedule: Weekly subcutaneous injections for 8–16 weeks
- Dose Range: 0.3 mg to 2 mg weekly (standard), up to 4 mg (advanced)
- Reconstitution: Use smaller volumes (0.4–0.8 mL) to match targeted units
- Storage: Keep lyophilized vials frozen; refrigerate after reconstitution
Dosing Protocol
Suggested once-weekly injection approach for stable and prolonged action.
- Weekly Dose: Start at 0.3 mg; gradually increase as research requires
- Frequency: Inject once per week subcutaneously
- Cycle Length: 8–16 weeks (can be extended based on objectives)
- Maximum Dose: Some protocols reach up to 4 mg weekly (requires multiple vials)
- Timing: Generally consistent day/time each week
Storage Instructions
Proper storage ensures peptide integrity.
- Lyophilized: Freeze until mixing (−20°C) or keep refrigerated if used soon
- Reconstituted: Refrigerate at 2–8°C
- Use within 30 days of mixing
- Avoid repeated freeze-thaw cycles
Supplies Needed
Ensure you have these on hand for an 8–16 week cycle (multiple vials required if dosing above 0.3–0.6 mg for extended weeks).
- Peptide Vials (2 mg each):
• 8 wks ≈ 2 vials (if standard protocol starts at 0.3 mg, then 0.6 mg)
• 12 wks ≈ 4 vials (increasing up to 1 mg weekly)
• 16 wks ≈ 8+ vials (if final weeks reach 2 mg or more) - Insulin Syringes:
• 8 wks ≈ 8
• 12 wks ≈ 12
• 16 wks ≈ 16
(Use smaller syringes if under 10 units per injection is unavoidable) - Bacteriostatic Water: 1× 30ml
- Alcohol Swabs: 1 box
Important Notes
Practical tips to enhance safety and consistency.
- Always use new, sterile insulin syringes and rotate injection sites.
- Administer weekly injections at the same time each week for consistent results.
- Monitor for any adverse reactions; discontinue if concerns arise.
- Log your weekly dosing and track progression over the research period.
How This Works
CJC-1295 DAC is a modified growth hormone-releasing hormone (GHRH) analog with a significantly extended half-life.
- DAC Modification: Extends half-life to maintain elevated GH and IGF-1
- GH Release: Stimulates the pituitary for sustained GH pulses
- Research Potential: Explored for muscle support, recovery, and metabolic studies
Potential Benefits & Side Effects
Individual responses can vary based on dosage and research objectives.
- May support improvements in muscle recovery and lean mass (research basis)
- Possible supportive role in fat metabolism
- Side effects may include mild injection-site redness or transient flushing
- Rarely, users report headache, water retention, or joint discomfort
Lifestyle Factors
Complementary methods for maximizing potential outcomes.
- Adopt a balanced, protein-rich diet for research on body composition
- Include regular exercise protocols with adequate rest
- Manage stress and maintain consistent sleep patterns
Injection Technique
Simple guidelines for safe weekly injections.
- Clean vial rubber stopper & injection site with alcohol swabs
- Insert needle at a 45–90° angle into subcutaneous tissue
- Inject slowly & rotate sites (abdomen, thigh, etc.)
Recommended Source
We recommend Pure Lab Peptides for high-purity CJC-1295 DAC.
Why Pure Lab Peptides?
- Verifies ≥99% purity through independent lab testing
- Trusted by researchers seeking reliable results
- Follows rigorous manufacturing standards for consistent quality
Important Note
This guide is for educational purposes only. Always consult a qualified healthcare provider before starting or modifying any therapy.
References
-
FDA Document
– Regulatory attachment for CJC-1295 -
PubMed
– Clinical study on CJC-1295 -
FDA Document
– Additional regulatory data on CJC-1295 -
American Journal of Physiology
– GH regulation research article -
Tocris
– Peptide reconstitution calculator -
Journal of Clinical Endocrinology & Metabolism
– CJC-1295 GH modulation study -
PubMed
– Additional CJC-1295 research data